Inhibrx Biosciences INBX
NASDAQ INBX
$96.99 -0.94 (-0.96%)
At close: Oct 2, 2026 · 4:00 PM EDT

Inhibrx Biosciences (INBX) Return on Invested Capital [ROIC] (2024 - 2026)

Updated

Inhibrx Biosciences (INBX) posted Return on Invested Capital [ROIC] of -107.20% for Q2 2026, down 14.65 percentage points from -92.55% a year earlier.

Analysis

Inhibrx Biosciences (INBX) Return on Invested Capital [ROIC] (2024 - 2026) Analysis & Trends

For FY2025, Inhibrx Biosciences' Return on Invested Capital [ROIC] came in at -111.53%, up 61.08 percentage points from FY2024.

  • In prior years, Inhibrx Biosciences' Return on Invested Capital [ROIC] was -172.60% in FY2024.
  • Quarterly Return on Invested Capital [ROIC] has run from a low of -212.43% in Q4 2024 to a high of -92.55% in Q2 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROIC (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 37.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 16.10%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 18.68%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 3.56%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 21.95%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 28.83%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 14.33%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -5.97%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 13.44%
10 Inhibrx Biosciences 1.43 Bn 1.43 Bn - -107.20%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -107.20%
Dec 31, 2025 -110.09%
Sep 30, 2025 -101.14%
Jun 30, 2025 -92.55%
Mar 31, 2025 -183.99%
Dec 31, 2024 -212.43%
Sep 30, 2024 -185.91%
API Access

Inhibrx Biosciences Return on Invested Capital [ROIC] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-invested-capital-%5Broic%5D&ticker=INBX&period=max&api_key=YOUR_API_KEY